Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer
Status:
Withdrawn
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This Phase II study is conducted to assess the safety and efficacy of CPI-613 in patients
with metastatic pancreatic cancer. The primary outcome measure is Overall Survival (OS). The
secondary outcome measures are: changes in CA 19-9, Quality of Life (QOL), Progression-Free
Survival (PFS), and safety.
Phase:
Phase 2
Details
Lead Sponsor:
Cornerstone Pharmaceuticals, Inc. Rafael Pharmaceuticals Inc.